Clinical Rheumatology

, Volume 26, Issue 9, pp 1495–1498 | Cite as

Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis

  • Lai-Shan Tam
  • Brian Tomlinson
  • Tanya T. Chu
  • Tena K. Li
  • Edmund K. Li
Original Article

Abstract

Patients with rheumatoid arthritis (RA) have increased cardiovascular mortality. TNF-α is a critical mediator of inflammation and metabolic response in patients with RA. Increased insulin resistance and dyslipidemia were known risk factors in patients with active RA, however, the regulation of these metabolic parameters by TNF-α is poorly understood. Neutralization of TNF-α with infliximab offers a unique opportunity to study TNF-α-mediated regulation of these metabolic parameters in RA. The aim of the study was to assess the in vivo TNF-α-mediated regulation of insulin resistance and lipids levels in RA. Nineteen patients with active RA treated with infliximab were prospectively followed for 14 weeks. Plasma lipids levels and insulin resistance were measured at baseline, 6 and 14 weeks after infliximab treatment. At week 14, the disease activity (DAS-28 score) improved significantly (p < 0.000), with a significant reduction in both C-reactive protein (p = 0.007) and erythrocyte sedimentation rate (p = 0.006) levels. The body weight did not change during the study period. After infliximab treatment, insulin resistance improved as reflected by the significant reduction in the Homeostasis Model Assessment Index. Total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, and apolipoprotein B (apoB) levels all increased significantly from baseline. Nonetheless, the atherogenic index, LDL-cholesterol/HDL-cholesterol ratio, and the LDL/apoB ratio remained unchanged. Infliximab improves insulin sensitivity and alters lipid profile in patients with active RA.

Keywords

Insulin resistance Lipid profile Rheumatoid arthritis TNF blocker 

Notes

Acknowledgment

Infliximab was provided by Janssen Pharmaceutica, Hong Kong.

References

  1. 1.
    Van_Doornum S, McColl G, Wicks IP (2002) Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 46:862–873PubMedCrossRefGoogle Scholar
  2. 2.
    Sattar N, McCarey DW, Capell H et al (2003) Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108:2957–2963PubMedCrossRefGoogle Scholar
  3. 3.
    Grundy SM, Brewer HB Jr, Cleeman JI et al (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109:433–438PubMedCrossRefGoogle Scholar
  4. 4.
    Dessein PH, Joffe BI (2006) Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 54:2765–2775PubMedCrossRefGoogle Scholar
  5. 5.
    Dessein PH, Joffe BI, Stanwix AE (2002) Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study. Arthritis Res 4:R12PubMedCrossRefGoogle Scholar
  6. 6.
    Feldmann M, Brennan FM, Maini RN (1996). Role of cytokines in rheumatoid arthritis. Ann Rev Immunol 14:397–440CrossRefGoogle Scholar
  7. 7.
    Cauza E, Cauza K, Hanusch-Enserer U et al (2002) Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr 114:1004–1007PubMedGoogle Scholar
  8. 8.
    Popa C, Netea MG, Radstake T et al (2005) Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 64:303–305PubMedCrossRefGoogle Scholar
  9. 9.
    Vis M, Nurmohamed MT, Wolbink G et al (2005) Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 32:252–255PubMedGoogle Scholar
  10. 10.
    Seriolo B, Paolino S, Sulli A et al (2006) Effects of anti-TNF-{alpha} treatment on lipid profile in patients with active rheumatoid arthritis. Ann N Y Acad Sci 1069:414–419PubMedCrossRefGoogle Scholar
  11. 11.
    Kiortsis DN, Mavridis AK, Filippatos TD et al (2006) Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 33:921–923PubMedGoogle Scholar
  12. 12.
    Dahlqvist SR, Engstrand S, Berglin E et al (2006) Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scand J Rheumatol 35:107–111PubMedCrossRefGoogle Scholar
  13. 13.
    Allanore Y, Kahan A, Sellam J et al (2006) Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin Chim Acta 365:143–148PubMedCrossRefGoogle Scholar
  14. 14.
    Kiortsis DN, Mavridis AK, Vasakos S et al (2005) Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 64:765–766PubMedCrossRefGoogle Scholar
  15. 15.
    Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C et al (2006) Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 24:83–86PubMedGoogle Scholar
  16. 16.
    Hotamisligil GS, Peraldi P, Budavari A et al (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271:665–668PubMedCrossRefGoogle Scholar
  17. 17.
    Chajek-Shaul T, Friedman G, Stein O et al (1989) Mechanism of the hypertriglyceridemia induced by tumor necrosis factor administration to rats. Biochim Biophys Acta 1001:316–324PubMedGoogle Scholar
  18. 18.
    Tchernof A, Lamarche B, Prud’Homme D et al (1996) The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 19:629–637PubMedCrossRefGoogle Scholar
  19. 19.
    Jacobsson LT, Turesson C, Gulfe A et al (2005) Treatment with tumor necrosis factor blockers is associated with a lower incidence of fist cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 32:1213–1218PubMedGoogle Scholar

Copyright information

© Clinical Rheumatology 2007

Authors and Affiliations

  • Lai-Shan Tam
    • 1
  • Brian Tomlinson
    • 1
  • Tanya T. Chu
    • 1
  • Tena K. Li
    • 1
  • Edmund K. Li
    • 1
  1. 1.Department of Medicine and TherapeuticsThe Chinese University of Hong KongHong KongChina

Personalised recommendations